Do analysts expect Intuitive Surgical stock to rebound?

Yes, the average 12-month price target implies over 20% upside from current levels.

What are the main risks facing Intuitive Surgical?

Key risks include regulatory scrutiny over instrument reuse and increasing competition from Chinese companies.

Is Intuitive Surgical a buy at its 52-week low?

Analysts see the stock as undervalued, but regulatory and competitive risks warrant caution. Long-term investment with monitoring of developments is advised.

Is Intuitive Surgical (ISRG) a Buy at 52-Week Lows?

Q: Why has Intuitive Surgical (ISRG) stock declined recently?

The stock fell over 29% in six months due to regulatory scrutiny over instrument reuse and concerns about Chinese competition.

Intuitive Surgical (ISRG) has dropped over 29% in six months, nearing its 52-week low due to regulatory scrutiny over instrument reuse and Chinese competition. However, analysts expect a rebound with an average 12-month price target implying over 20% upside.

Intuitive Surgical, Inc. (NASDAQ: ISRG) has declined more than 29% over the past six months and is now trading close to its 52-week lows. The downward pressure stems from regulatory scrutiny regarding instrument reuse and concerns over Chinese competition. However, the Street expects the stock to rebound, with analysts’ 12-month average price target suggesting more than 20% upside.

Reasons for the Decline

Regulatory Scrutiny

Intuitive Surgical faces increased regulatory scrutiny over its instrument reuse practices, raising investor concerns about potential revenue impact.

Chinese Competition

The emergence of Chinese competitors in the robotic surgery market threatens Intuitive's market share, particularly in Asian markets.

Analyst Outlook

Despite the headwinds, analysts believe the stock is undervalued at current levels. The average 12-month price target implies over 20% upside, supported by the company's strong core business and leadership in robotic surgery.

What This Means for Investors

Trading at 52-week lows, ISRG presents a potential opportunity for long-term investors, but regulatory and competitive risks warrant caution. Monitoring regulatory developments and competitor performance is advised before making investment decisions.